1 Min Read
Oct 18 (Reuters) - Adaptimmune Therapeutics Plc :
* Adaptimmune Therapeutics Plc - adaptimmune announces initiation of triple tumor study to evaluate its spear t-cell therapy targeting MAGE-A10 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.